The newly formed commission announced its comprehensive review of government waste will begin by carefully quarantining the billions in federal subsidies currently keeping its co-director’s companies solvent.
The Department of Government Efficiency (DOGE), tasked with identifying $2 trillion in federal budget cuts, released its preliminary framework on Tuesday. According to a memorandum submitted to the transition team, the advisory board will demand unprecedented austerity across all federal agencies, while strictly quarantining the estimated $15.3 billion in active government contracts currently keeping co-director Elon Musk’s aerospace empire solvent.
The 40-page blueprint targets widespread reductions in what the commission termed "low-ROI civic expenditures," a category encompassing the Environmental Protection Agency, the Department of Education, and civilian highway maintenance. Concurrently, the document requests that the Department of Defense immediately fast-track a multi-billion-dollar exclusive procurement agreement for Starshield satellite terminals, classifying the expenditure as a critical efficiency maneuver.
Our objective is to mercilessly excise bureaucratic bloat from the administrative state, ensuring that American tax dollars are no longer squandered on redundant social safety nets when they could be directly deposited into the SpaceX corporate treasury.
Records obtained from the Senate Appropriations Committee indicate the efficiency panel has already flagged the National Labor Relations Board for complete defunding. The board is currently pursuing multiple cases against Musk’s companies for illegal union-busting practices, a regulatory overlap the DOGE memo describes as a glaring example of the federal government duplicating efforts that the free market has already resolved through targeted employee terminations.
Vivek Ramaswamy, who shares leadership duties of the nongovernmental advisory group, concurred with the findings during a morning media appearance. Speaking to reporters, Ramaswamy noted the commission is also reviewing ways to streamline the Food and Drug Administration, arguing that eliminating clinical trial oversight would represent a massive cost-saving victory for the American taxpayer, and entirely coincidentally, for the portfolio of Roivant Sciences, the biotech holding company he founded.